What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
"We are encouraged by this data and the potential benefit that trem-cel in combination with Mylotarg may offer to patients in a disease that has extremely poor outcomes even after transplant," said Eyal Attar, Vor Bio's Chief Medical Officer. "With this data, we plan to explore a registrational trial while we continue to pursue other synergistic opportunities for Vor Bio's platform such as VCAR33ALLO and VADC45." Thursday, Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.
Vor Biopharma Inc.（納斯達克：VOR）週四發佈了其進行中的VBP101臨床試驗的新臨床數據。該試驗針對復發/難治性急性髓系白血病（AML）患者進行，先接受trem-cel，然後再接受Mylotarg。
Pfizer Inc's (NYSE:PFE) Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients two years and older.
輝瑞公司（紐交所：PFE）的Mylotarg適用於新診斷的成人CD33陽性AML，以及復發或難治的成人和兩歲及以上的兒童的CD33陽性急性髓系白血病（AML）。
The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.
該數據顯示出可靠的移植、Mylotarg的靶向毒性抑制、Mylotarg治療窗口的拓寬以及早期患者受益的證據。
"We are encouraged by this data and the potential benefit that trem-cel in combination with Mylotarg may offer to patients in a disease that has extremely poor outcomes even after transplant," said Eyal Attar, Vor Bio's Chief Medical Officer. "With this data, we plan to explore a registrational trial while we continue to pursue other synergistic opportunities for Vor Bio's platform such as VCAR33ALLO and VADC45."
Vor Bio首席醫學官Eyal Attar表示：「我們對這個數據以及trem-cel與Mylotarg聯合使用可能爲患者帶來的潛在益處感到鼓舞。目前即使移植後，AML的治療效果仍然非常糟糕。根據這個數據，我們計劃在繼續尋求Vor Bio平台的其他協同機會，如VCAR33ALLO和VADC45的同時，探索註冊試驗。」
The data released included 18 patients treated with trem-cel of which ten had received Mylotarg as of the data cut-off date of July 19, 2024. The data demonstrated:
發佈的數據包括18名接受trem-cel治療的患者，其中10名在2024年7月19日的截止日期之前已經接受了Mylotarg治療。數據顯示：
- Reliable engraftment, with 100% of patients achieving primary neutrophil engraftment (median 9 days) and robust platelet recovery (median 16.5 days).
- Shielding of the blood system, with maintained neutrophil and platelet counts across multiple Mylotarg doses of 0.5, 1, and 2 mg/m2.
- Early evidence suggests patient benefit as measured by relapse-free survival compared to published high-risk AML comparators.
- 可靠的移植，所有患者均實現了主要中性粒細胞移植（中位數爲9天）和大幅恢復血小板（中位數爲16.5天）。
- 對血液系統的保護，在多個Mylotarg劑量（0.5、1和2 mg/m2）下，保持中性粒細胞和血小板計數。
- 根據與已發佈的高風險AML對照組相比的無復發生存率的早期證據，表明患者受益。
Vor Bio plans to approach the FDA to discuss a pivotal trial design for trem-cel + Mylotarg by around the end of the year.
Vor Bio計劃在年底左右與FDA商討trem-cel + Mylotarg的關鍵試驗設計。
Vor Bio announced a new preclinical asset, VADC45, which has several potential opportunities in oncology, gene therapy, and autoimmune disorders.
Vor Bio宣佈了一個新的臨床前資產VADC45，在腫瘤學、基因療法和自身免疫性疾病等領域有幾個潛在機會。
The company said cash, cash equivalents, and marketable securities were $85.9 million as of June 30, 2024, projected to fund operations into the second half of 2025.
公司表示，截至2024年6月30日的現金、現金等價物和可交易證券總額爲8590萬美元，預計資金可支持運營至2025年下半年。
Price Action: VOR stock is up 28.5%at $1.06 at last check Friday.
價格走勢：VOR股票最新報價爲1.06美元，上漲28.5%。
Photo via Shutterstock
圖片來自shutterstock。
- GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug.
- GSK的哮喘藥物在第三階段研究中達到了與吸菸者肺相關的主要目標，準備與Amgen/AstraZeneca的藥物競爭。
